HCV microelimination in harm reduction centres has benefits beyond HCV cure but is hampered by high reinfection rates
Open Access
- 13 September 2022
- journal article
- research article
- Published by Elsevier in JHEP Reports
- Vol. 4 (12) , 100580
Abstract
No abstract availableKeywords
Funding Information
- Asociación Española para el Estudio del Hígado
- Instituto de Salud Carlos III
- European Social Fund Plus
- Societat Catalana de Digestologia
- Gilead Sciences (IN-ES-987-5349)
This publication has 27 references indexed in Scilit:
- HCV epidemiology in high-risk groups and the risk of reinfectionJournal of Hepatology, 2016
- Implementation of rapid HIV and HCV testing within harm reduction programmes for people who inject drugs: a pilot studyAIDS Care, 2016
- Impact of unstable housing on all-cause mortality among persons who inject drugsBMC Public Health, 2015
- Regional alcohol consumption and alcohol-related mortality in Great Britain: novel insights using retail sales dataBMC Public Health, 2015
- High Rates of Hepatitis C Virus Reinfection and Spontaneous Clearance of Reinfection in People Who Inject Drugs: A Prospective Cohort StudyPLOS ONE, 2013
- The longitudinal association between homelessness, injection drug use, and injection-related risk behavior among persons with a history of injection drug use in Baltimore, MDDrug and Alcohol Dependence, 2013
- Stigma, discrimination and the health of illicit drug usersDrug and Alcohol Dependence, 2007
- Natural History of Hepatitis CClinics in Liver Disease, 2005
- Protection against persistence of hepatitis CThe Lancet, 2002
- Self-report among injecting drug users: A reviewDrug and Alcohol Dependence, 1998